• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia >Hypericin uptake: A prognostic marker for survival in high-grade glioma.
【24h】

Hypericin uptake: A prognostic marker for survival in high-grade glioma.

机译：金丝桃素的摄取：高级别神经胶质瘤生存的预后标志物。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Currently adjuvant chemotherapy for glioblastoma patients can prolong survival time relative to patients who receive only surgery and radiotherapy. Despite these improvements and experimental and clinical efforts the prognosis for glioblastoma patients remains poor. At present, interest is focused on individual prognostic factors influencing patient responses to therapy. Photodynamic therapy may be a promising therapeutic option in the treatment of glioblastoma. In this investigation we examined whether uptake of hypericin (HY), a fluorescent photosensitization agent, by ex vivo glioblastoma cell lines correlates with prognosis of the individual from which the cell lines were derived. Twelve primary human glioma cell cultures were incubated with 20 mumol HY. Fluorescence intensity was measured using fluorescence microscopy. Three patients suffered from an anaplastic astrocytoma, WHO grade III, nine had a glioblastoma, WHO grade IV. In 6/12 patients complete tumour resection was possible. The mean survival time of the six patients in whom complete tumour resection was performed was 26 months, compared with 5 months for those who underwent incomplete resection. Eleven patients received radiation therapy. The five patients who received chemotherapy survived for a mean duration of 26 months, compared with the seven patients who survived for a mean duration of 5 months without chemotherapy. Statistical analysis using a parametric survival model based on the Weibull distribution showed that fluorescence intensity was the variable with the lowest p-value associated with survival (p=0.0225). An increase of 553 arbitrary units of fluorescence intensity is predicted to double survival time. Uptake of HY, a lipophilic molecule, is assumed to be related to low-density lipoprotein (LDL) uptake and metabolism. Cell proliferation is associated with a high turnover of cholesterol and membrane growth, which is related to cholesterol uptake by LDL. In summary, HY uptake by ex vivo glioblastoma cell cultures seems to bepositively associated with survival of patients with malignant glioma.
机译：目前，相对于仅接受手术和放射疗法的患者，胶质母细胞瘤患者的辅助化疗可以延长生存时间。尽管有这些改进以及实验和临床努力，但胶质母细胞瘤患者的预后仍然很差。目前，关注的重点是影响患者对治疗反应的个体预后因素。在胶质母细胞瘤的治疗中，光动力疗法可能是有前途的治疗选择。在这项研究中，我们检查了离体胶质母细胞瘤细胞系对金丝桃素（HY）（一种荧光光敏剂）的摄取是否与细胞系来源个体的预后相关。将十二种原代人神经胶质瘤细胞培养物与20μmolHY孵育。使用荧光显微镜法测量荧光强度。三名患有间变性星形细胞瘤的患者，世卫组织三级，九名患有胶质母细胞瘤，世卫组织四级。在6/12的患者中，可能会完全切除肿瘤。进行完全肿瘤切除术的6例患者的平均生存时间为26个月，而接受不完全切除术的患者为5个月。 11例患者接受了放射治疗。五名接受化学疗法的患者平均存活时间为26个月，而七名未经化学疗法的患者平均存活时间为5个月。使用基于Weibull分布的参数生存模型进行统计分析表明，荧光强度是变量，具有与生存相关的最低p值（p = 0.0225）。荧光强度增加553个任意单位预计将使生存时间增加一倍。 HY（一种亲脂性分子）的摄取被认为与低密度脂蛋白（LDL）的摄取和代谢有关。细胞增殖与胆固醇和膜生长的高转换有关，这与LDL吸收胆固醇有关。总之，离体胶质母细胞瘤细胞培养物对HY的摄取似乎与恶性神经胶质瘤患者的生存呈正相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号